We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
“The high demand for places on the study underlines just how prevalent skin conditions such as psoriasis are, and how keen sufferers are to try something new and natural to alleviate their symptoms. If we can, we want to help as many people as possible".
Above note just shows what kind of consumer demand there is. Thats people willing to take part in a study that may have side effects and might not work.
When results are published demand for something non evasive and inexpensive going to be much higher.
Stuart is no fool and knows exactly what the market would like to see. In his boots I'd hold off right till the end of the month before releasing the results, because then you will be better able to answer the host of questions about what comes next.
Expect armed with the information he clearly has now, he can use that time to secure realistic supply times, and perhaps broadly discuss study findings with psoriasis association leaders who will be more than interested in securing ample supplies for their millions of members... Some danger in the last sentence as could be viewed as highly market sensitive information, so doubt actual sharing of exact info hence the word "broadly", as an overview, dependant of level of trust.
That way when study results are shared via RNS, hes in a great position to continue momentum. Thats when obviously asked these pre primed questions at the next broadcast interview. Which will be expected on study info release day.
Wouldn't mind being in his shoes currently for company development and expansion.
Know some investors have stated we could have commanded higher prices for our products, and believe they are right.
But happy to see them where they are believed to be so more applicants can be in a position to benefit. Also the lower price will command the market.
Stuart is no fool and knows exactly what the market would like to see. In his boots I'd hold off right till the end of the month before releasing the results, because then you will be better able to answer the host of questions about what comes next.
Expect armed with the information he clearly has now, he can use that time to secure realistic supply times, and perhaps broadly discuss study findings with psoriasis association leaders who will be more than interested in securing ample supplies for their millions of members... Some danger in the last sentence as could be viewed as highly market sensitive information, so doubt actual sharing of exact info hence the word "broadly", as an overview, dependant of level of trust.
That way when study results are shared via RNS, hes in a great position to continue momentum. Thats when obviously asked these pre primed questions at the next broadcast interview. Which will be expected on study info release day.
Wouldn't mind being in his shoes currently for company development and expansion.
Know some investors have stated we could have commanded higher prices for our products, and believe they are right.
But happy to see them where they are believed to be so more applicants can be in a position to benefit. Also the lower price will command the market.
It’s interesting to see no buyers pre results .I guess small investors are hedging and bigger investors wait to see results .
Belgrano.
Weird you should say that, talking to a friend who has it and it makes his life a misery, a massive impact on his mental wellbeing. My wife also said a teaching assistant where she works has it so bad he doesn't sleep, if he does he stretches himself with the bed clothes covered in blood.
As you say outside being a shareholder this could really completely turn around people's lives.
I'm pleased to invest my hard earned, in a company that's going to bring so much relief to sufferers throughout the world.
Doesn't take much to lower your moral and kill your self confidence, even a very mild dose of psoriasis in the wrong spot can do it, have also heard of acute sufferers symptoms being cleared in the study. Its not impossible to get to many thousands of subscribers this year... dont think 2 years... much quicker than that.
Looking at the figures produced by the Psoriasis Assoc I was struck by their estimate that 10% of sufferers in the UK have considered suicide . Assuming this comes down to 500000 sufferers it still gives a figure of 50000 or 10% who are terribly affected psychologically. The current study only concerns moderate cases but this horrifying figure underlines the hope pinned on a very positive result to the trial .